exaluren inhaled (ELX-02 inhaled) / Eloxx Pharma - LARVOL DELTA

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update (GlobeNewswire) - "Eloxx Pharmaceuticals, Inc...today reported its financial results for the three months ended March 31, 2022 and provided a business update....Evaluation of inhaled (nebulizer-based) delivery of the current subcutaneous formulation of ELX-02 remains ongoing. We believe that the increased drug exposure in the lung versus plasma with inhaled delivery has the potential to further improve the activity of ELX-02. We remain on track to submit an Investigational New Drug (IND) application in the second half of 2022."

IND • Cystic Fibrosis